PEG-MGF
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
PEG-MGF is Mechano Growth Factor with a polyethylene glycol (PEG) chain attached. MGF itself is the IGF-1Ec splice variant — the C-terminal peptide your own muscle produces locally in response to mechanical loading, the signal that wakes dormant satellite cells (the full MGF mechanism story lives in IGF-1 LR3 and MGF — the IGF-1 axis muscle cluster). The problem with raw MGF is that its circulating half-life is measured in minutes, making it practically unusable for anything but an immediate-post-workout local injection. Pegylation extends that half-life from minutes to hours, allowing systemic distribution. In practice, essentially all research-peptide “MGF” use is PEG-MGF for exactly this reason.
This article treats PEG-MGF as the delivery-form sibling of the MGF covered in IGF-1 LR3 and MGF — the IGF-1 axis muscle cluster — same molecule, same satellite-cell mechanism, the PEG group is purely a pharmacokinetic modification. The dosing and protocol detail (PEG-MGF 200–400 mcg IM, 2–3×/week, trained muscle, post-workout window) is documented there; this entry captures PEG-MGF’s identity, mechanism, and evidence status rather than re-deriving the protocol.
What does it do in my body?
PEG-MGF “activates satellite cells and promotes muscle growth through IGF-1 splice variant pathways,” with pegylation enabling systemic rather than purely local action. Mechanistically: muscle satellite cells sit dormant in G0; mechanical damage releases MGF; MGF drives those cells into the cell cycle (proliferation without premature differentiation), expanding the satellite-cell pool that then fuses with damaged fibers and adds new myonuclei. The PEG group doesn’t change that biology — it just keeps the molecule in circulation long enough to reach muscle systemically instead of being cleared within minutes. Full mechanism in IGF-1 LR3 and MGF — the IGF-1 axis muscle cluster.
How can it help me?
- Where the science stands: **** — 0 published studies, preclinical/community only
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
Lighter surface than the directly-administered IGF-1 analogs (local action, smaller potency): injection-site reactions and mild localized effects are the main reported issues, with IGF-axis class cautions applying only at a theoretical level. There is no human safety record for PEG-MGF specifically.
Contraindications across the IGF-axis class: active cancer or cancer history (mitogenic concern), pregnancy/breastfeeding, uncontrolled diabetes.
Regulatory status: Not FDA-approved; research-chemical; WADA-banned. Unlike Somatropin (HGH) — an approved prescription drug — PEG-MGF has no approval pathway and, unlike even IGF-1 DES, no published clinical studies at all behind it.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
Community protocol (documented in IGF-1 LR3 and MGF — the IGF-1 axis muscle cluster): PEG-MGF 200–400 mcg IM into trained muscle, 2–3×/week, within 1–2 hours post-workout, training days only — the satellite-cell mechanism requires the mechanical-damage trigger, so “inject without training” misses the point entirely.
What should I avoid combining — and what's synergistic?
PEG-MGF doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
PEG-MGF is Mechano Growth Factor — the IGF-1Ec splice variant your own muscle produces locally in response to mechanical loading — with a polyethylene glycol chain attached to stretch its circulating half-life from minutes to hours. It is the thinnest evidence base in this GH/IGF reference family: zero published human or animal studies specifically on the PEGylated form, with all mechanism support borrowed from the general MGF preclinical literature. This article states that gap plainly rather than papering over it.
| Class | MGF (IGF-1Ec splice variant) with a polyethylene glycol (PEG) chain attached for extended half-life |
| Mechanism (one line) | Activates dormant muscle satellite cells via IGF-1 splice-variant pathways; pegylation extends half-life from minutes to hours, enabling systemic (not just local) action |
| Evidence base | **** — 0 published studies, preclinical/community only |
| Safety record | Lighter surface than the potent IGF-1 analogs (local action, smaller potency); IGF-axis class cautions apply at theoretical level; no human safety record |
| Regulatory status | Not FDA-approved; research-chemical; WADA-banned |
What it is
PEG-MGF is Mechano Growth Factor with a polyethylene glycol (PEG) chain attached. MGF itself is the IGF-1Ec splice variant — the C-terminal peptide your own muscle produces locally in response to mechanical loading, the signal that wakes dormant satellite cells (the full MGF mechanism story lives in IGF-1 LR3 and MGF — the IGF-1 axis muscle cluster). The problem with raw MGF is that its circulating half-life is measured in minutes, making it practically unusable for anything but an immediate-post-workout local injection. Pegylation extends that half-life from minutes to hours, allowing systemic distribution. In practice, essentially all research-peptide “MGF” use is PEG-MGF for exactly this reason.
This article treats PEG-MGF as the delivery-form sibling of the MGF covered in IGF-1 LR3 and MGF — the IGF-1 axis muscle cluster — same molecule, same satellite-cell mechanism, the PEG group is purely a pharmacokinetic modification. The dosing and protocol detail (PEG-MGF 200–400 mcg IM, 2–3×/week, trained muscle, post-workout window) is documented there; this entry captures PEG-MGF’s identity, mechanism, and evidence status rather than re-deriving the protocol.
How it works
PEG-MGF “activates satellite cells and promotes muscle growth through IGF-1 splice variant pathways,” with pegylation enabling systemic rather than purely local action. Mechanistically: muscle satellite cells sit dormant in G0; mechanical damage releases MGF; MGF drives those cells into the cell cycle (proliferation without premature differentiation), expanding the satellite-cell pool that then fuses with damaged fibers and adds new myonuclei. The PEG group doesn’t change that biology — it just keeps the molecule in circulation long enough to reach muscle systemically instead of being cleared within minutes. Full mechanism in IGF-1 LR3 and MGF — the IGF-1 axis muscle cluster.
What the research shows
This is the thinnest evidence base of any compound in the GH/IGF reference family, stated plainly. Peptidelist grades PEG-MGF Anecdotal: 0 studies cited, 0 human trials — “No published clinical studies were found on PubMed for PEG-MGF. Evidence is limited to preclinical research or community reports.” 0035 kept PEG-MGF at Tier D / provisional: no published human trials.
The supporting science is the broader MGF preclinical literature (the Goldspink-group satellite-cell work) covered under IGF-1 LR3 and MGF — the IGF-1 axis muscle cluster — but note that body of work is on MGF generally, not on the PEGylated form specifically. There are no PEG-MGF-specific human studies. Anyone citing “studies on PEG-MGF” is borrowing from the general MGF literature.
Real-world protocol
The information here is educational only. PEG-MGF is a research chemical, not an FDA-approved drug, and carries no PEG-MGF-specific human trial data. This is not medical advice.
Community protocol (documented in IGF-1 LR3 and MGF — the IGF-1 axis muscle cluster): PEG-MGF 200–400 mcg IM into trained muscle, 2–3×/week, within 1–2 hours post-workout, training days only — the satellite-cell mechanism requires the mechanical-damage trigger, so “inject without training” misses the point entirely.
Side effects & management
Lighter surface than the directly-administered IGF-1 analogs (local action, smaller potency): injection-site reactions and mild localized effects are the main reported issues, with IGF-axis class cautions applying only at a theoretical level. There is no human safety record for PEG-MGF specifically.
Contraindications across the IGF-axis class: active cancer or cancer history (mitogenic concern), pregnancy/breastfeeding, uncontrolled diabetes.
Regulatory status
Not FDA-approved; research-chemical; WADA-banned. Unlike Somatropin (HGH) — an approved prescription drug — PEG-MGF has no approval pathway and, unlike even IGF-1 DES, no published clinical studies at all behind it.
Sources
- — thepeptidelist.com PEG-MGF profile: pegylation half-life extension, satellite-cell mechanism, 0 studies / anecdotal tier, research-only status.
- — grading: PEG-MGF Tier D/provisional (lines 262–264); the safety framing.
Content migrated from gh-igf-reference-cluster.md (2026-06-10 build) per the 2026-07-16 cluster-elimination directive — no facts added or removed from the source article’s PEG-MGF section.
See also: Somatropin (HGH), IGF-1 DES, IGF-1 LR3 and MGF — the IGF-1 axis muscle cluster, CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, MK-677 (Ibutamoren).
Sources & references
- — thepeptidelist.com PEG-MGF profile: pegylation half-life extension, satellite-cell mechanism, 0 studies / anecdotal tier, research-only status.
- — grading: PEG-MGF Tier D/provisional (lines 262–264); the safety framing.
Content migrated from gh-igf-reference-cluster.md (2026-06-10 build) per the 2026-07-16 cluster-elimination directive — no facts added or removed from the source article’s PEG-MGF section.
See also: Somatropin (HGH), IGF-1 DES, IGF-1 LR3 and MGF — the IGF-1 axis muscle cluster, CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, MK-677 (Ibutamoren).